ATE515508T1 - Verbindungen für die die zellmembran im wesentlichen undurchlässig ist und ihre anwendung - Google Patents

Verbindungen für die die zellmembran im wesentlichen undurchlässig ist und ihre anwendung

Info

Publication number
ATE515508T1
ATE515508T1 AT00965636T AT00965636T ATE515508T1 AT E515508 T1 ATE515508 T1 AT E515508T1 AT 00965636 T AT00965636 T AT 00965636T AT 00965636 T AT00965636 T AT 00965636T AT E515508 T1 ATE515508 T1 AT E515508T1
Authority
AT
Austria
Prior art keywords
compounds
application
cell membrane
essentially impermeable
arsenoxide
Prior art date
Application number
AT00965636T
Other languages
English (en)
Inventor
Philip Hogg
Neil Donoghue
Original Assignee
Newsouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newsouth Innovations Pty Ltd filed Critical Newsouth Innovations Pty Ltd
Application granted granted Critical
Publication of ATE515508T1 publication Critical patent/ATE515508T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C07F9/78—Aromatic compounds containing amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/80—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
AT00965636T 1999-09-20 2000-09-20 Verbindungen für die die zellmembran im wesentlichen undurchlässig ist und ihre anwendung ATE515508T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ2967A AUPQ296799A0 (en) 1999-09-20 1999-09-20 A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
PCT/AU2000/001143 WO2001021628A1 (en) 1999-09-20 2000-09-20 A substantially cell membrane impermeable compound and use thereof

Publications (1)

Publication Number Publication Date
ATE515508T1 true ATE515508T1 (de) 2011-07-15

Family

ID=3817132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965636T ATE515508T1 (de) 1999-09-20 2000-09-20 Verbindungen für die die zellmembran im wesentlichen undurchlässig ist und ihre anwendung

Country Status (9)

Country Link
US (3) US7074766B1 (de)
EP (1) EP1228076B1 (de)
JP (1) JP4707294B2 (de)
AT (1) ATE515508T1 (de)
AU (1) AUPQ296799A0 (de)
CA (1) CA2385322C (de)
ES (1) ES2366467T3 (de)
WO (1) WO2001021628A1 (de)
ZA (1) ZA200202272B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) * 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
AUPR598901A0 (en) * 2001-06-28 2001-07-19 Unisearch Limited Inhibition of angiogenesis by targeting protein tyrosine phosphatases
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
AUPR874601A0 (en) * 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
EP1474128B1 (de) * 2002-01-07 2016-06-01 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinsäure,s-dimethylarsino-2-thiobenzoesäure, s-(dimethylarsino)-glutathion zur krebsbehandlung
CN101863958B (zh) * 2002-11-07 2012-07-18 新南创新私人有限公司 对线粒体通透性转换的诱导
AU2008200304B2 (en) * 2002-11-07 2012-02-02 Newsouth Innovations Pty Limited Induction of the mitochondrial permeability transition
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
CN101595115B (zh) * 2006-11-01 2012-07-18 新南部创新有限公司 有机-氧化砷化合物及其用途
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
WO2009043114A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Arsenoxide compound and method of use
US10828275B2 (en) 2014-10-24 2020-11-10 Newsouth Innovations Pty Limited Selective targeting of procoagulant platelets
CN114206844B (zh) 2019-04-12 2025-01-28 癌症医学和细胞生物学百年研究所 缀合物及其作为成像剂的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2370092A (en) * 1942-05-04 1945-02-20 Parke Davis & Co Organic amine derivatives and method of obtaining same
US2409291A (en) * 1942-05-19 1946-10-15 Squibb & Sons Inc Chemotherapeutic sulfanilamide derivatives
US2465308A (en) * 1946-11-27 1949-03-22 Hoffmann La Roche Arsenoso compounds and method of preparation
US2664432A (en) * 1947-01-28 1953-12-29 Ernst A H Friedheim Heterocyclic metal and sulfur organic compounds
US2553515A (en) * 1948-12-11 1951-05-15 Hoffmann La Roche N-(p-arsenoso-benzyl)-urea
US2951766A (en) * 1957-07-15 1960-09-06 Le Roy A White Antiseptic plastic
FR2013455A1 (en) * 1968-07-22 1970-04-03 Erasme Organo arsenic or organo antimony peni - cillins
BE786573A (fr) 1971-07-20 1973-01-22 Hoechst Ag Medicament a base de composes arsenicaux organiques et de derives du benzimidazole
JPS53124606A (en) * 1977-04-04 1978-10-31 Sankyo Co Ltd Purification of albumin
FR2640269B1 (fr) * 1988-12-13 1991-03-15 Maes Ludo Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant
US5270196A (en) 1989-10-20 1993-12-14 Bristol-Myers Squibb Company Arylsulfatase from streptomyces
FR2684382B1 (fr) * 1991-12-02 1994-10-21 Rhone Merieux Medicaments et preparations pures de dichlorhydrate de melarsomine, leur procede d'obtention et produits intermediaires obtenus.
WO1998051297A1 (en) 1997-05-14 1998-11-19 The University Of New Mexico Inhibition of cell surface protein disulfide isomerase
CN1282218A (zh) 1997-10-15 2001-01-31 波拉克斯生物药品 使用砷化合物治疗原发性及转移性肿瘤疾病的组合物及方法
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
FR2781674B1 (fr) 1998-07-31 2002-06-28 Inst Nat Sante Rech Med Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
AU769756B2 (en) 1998-11-03 2004-02-05 Mitokor Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
WO2000079274A2 (en) 1999-06-22 2000-12-28 Mitokor Methods for assaying subcellular conditions using energy transfer
AUPQ296799A0 (en) * 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) * 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
AUPR874601A0 (en) 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells

Also Published As

Publication number Publication date
EP1228076B1 (de) 2011-07-06
US7674775B2 (en) 2010-03-09
HK1048818A1 (en) 2003-04-17
CA2385322A1 (en) 2001-03-29
US20070037996A1 (en) 2007-02-15
CA2385322C (en) 2011-01-25
JP2003509516A (ja) 2003-03-11
EP1228076A4 (de) 2002-11-06
JP4707294B2 (ja) 2011-06-22
ZA200202272B (en) 2003-07-25
US7074766B1 (en) 2006-07-11
WO2001021628A1 (en) 2001-03-29
US20070037995A1 (en) 2007-02-15
AUPQ296799A0 (en) 1999-10-14
ES2366467T3 (es) 2011-10-20
US7498406B2 (en) 2009-03-03
EP1228076A1 (de) 2002-08-07

Similar Documents

Publication Publication Date Title
AUPQ296799A0 (en) A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
TR200102800T2 (tr) Yeni bileşikler.
AU2002310156A1 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds
AU7278500A (en) Fungicides
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
TR200200225T2 (tr) İkameli okzo azahetrosiklil bileşikleri
FR2848850B1 (fr) Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates.
DE69626218D1 (de) 4-pyrimidinyl- or 4-pyrazinyl-piperazinyl-phenyl-oxazolidinon derivate, deren herstellung und deren verwendung als antibakterielle mittel
GB0011203D0 (en) Chemical compounds
IT1271325B (it) Composti diastereomericamente puri derivati da 3-oxo e 3-tioxo-4-azaandrostani e loro uso come antiandrogeni
EP0798288A4 (de) Tricyclische verbindungen
ATE266030T1 (de) 1,4,7,10-tetraazabicyclo(8.2.2)tetradecan-2-on, verfahren zu ihrer herstellung und ihrer verwendung für die herstellung von tetraazamacrocyclen
TW200606581A (en) A chemically amplified positive resist composition, a haloester derivative and a process for producing the same
TR200201683T2 (tr) İkameli fenil-piperazin türevleri, bunların hazırlanması ve kullanımları
PE84299A1 (es) Compuestos policiclicos parcialmente hidrogenados
NO981393L (no) Guanidinoproteasehemmere
WO2003035651A3 (fr) Derives de l'artemisinine, et leurs utilisations dans le traitement du paludisme
TR200200347T2 (tr) 1,4-İkameli 4,4-diaril sikloheksanlar.
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
TR200001819T2 (tr) COPD tedavi yöntemi.
TR199800210T2 (xx) Didepsipeptid temelli endoparazitisid kompozisyonlar, yeni didepsipeptidler ve bunlar�n �retimi i�in i�lemler.
ATE338054T1 (de) 17alpha-fluoralkylsteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE319708T1 (de) Azol- oder triazol-derivate, verfahren zu deren herstellung und ihre verwendung als fungizide
AR020785A1 (es) Nuevos procedimientos quimicos
IT1309601B1 (it) Processo per la preparazione di 1,4,7,10 tetraazaciclododecano.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties